YMAB
Income statement / Annual
Last year (2023), Y-mAbs Therapeutics, Inc.'s total revenue was $84.82 M,
an increase of 29.96% from the previous year.
In 2023, Y-mAbs Therapeutics, Inc.'s net income was -$21.43 M.
See Y-mAbs Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$84.82 M
|
$65.27 M
|
$34.90 M
|
$20.75 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$11.42 M |
$7.57 M |
$2.51 M |
$2.20 M |
$166,000.00 |
$29,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
$73.40 M |
$57.70 M |
$32.38 M |
$18.55 M |
-$166,000.00 |
-$29,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.87 |
0.88 |
0.93 |
0.89 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$54.22 M
|
$91.57 M
|
$93.25 M
|
$93.70 M
|
$63.49 M
|
$34.27 M
|
$14.31 M
|
$13.86 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$44.79 M
|
$19.51 M
|
$8.96 M
|
$4.94 M
|
$3.18 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$44.86 M
|
$60.94 M
|
$54.57 M
|
$44.79 M
|
$19.51 M
|
$8.96 M
|
$4.94 M
|
$3.18 M
|
| Other Expenses |
$0.00 |
$0.00 |
$62.01 M |
-$2.20 M |
$0.00 |
-$44,000.00 |
$83,000.00 |
-$18,000.00 |
| Operating Expenses |
$99.08 M |
$152.51 M |
$147.82 M |
$138.48 M |
$83.00 M |
$43.23 M |
$19.24 M |
$17.04 M |
| Cost And Expenses |
$110.49 M |
$160.08 M |
$150.33 M |
$138.48 M |
$83.00 M |
$43.23 M |
$19.24 M |
$17.04 M |
| Interest Income |
$0.00 |
$643,000.00 |
$1.85 M |
$598,000.00 |
$1.98 M |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$757,000.00 |
$1.85 M |
$598,000.00 |
$1.98 M |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$735,000.00
|
$839,000.00
|
$782,000.00
|
$396,000.00
|
$166,000.00
|
$29,000.00
|
$19.24 M
|
$17.04 M
|
| EBITDA |
-$25.67 M
|
-$94.73 M
|
-$54.49 M
|
-$119.54 M
|
-$82.84 M
|
-$43.20 M
|
$83,000.00
|
-$18,000.00
|
| EBITDA Ratio |
-0.3 |
-1.45 |
-3.31 |
-5.67 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-0.3
|
-1.45
|
-3.31
|
-5.78
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$4.81 M
|
-$757,000.00
|
$60.16 M
|
$598,000.00
|
$1.98 M
|
-$44,000.00
|
$83,000.00
|
-$18,000.00
|
| Income Before Tax |
-$20.87 M |
-$95.57 M |
-$55.28 M |
-$119.34 M |
-$81.03 M |
-$43.27 M |
-$19.16 M |
-$17.06 M |
| Income Before Tax Ratio
|
-0.25
|
-1.46
|
-1.58
|
-5.75
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$561,000.00 |
$757,000.00 |
$1.07 M |
-$994,000.00 |
-$2.14 M |
-$44,000.00 |
-$19.24 M |
-$17.04 M |
| Net Income |
-$21.43 M |
-$96.33 M |
-$56.35 M |
-$118.34 M |
-$78.89 M |
-$43.27 M |
-$19.16 M |
-$17.06 M |
| Net Income Ratio |
-0.25 |
-1.48 |
-1.61 |
-5.7 |
0 |
0 |
0 |
0 |
| EPS |
-0.49 |
-2.2 |
-1.3 |
-2.95 |
-2.24 |
-1.5 |
-0.58 |
-0.51 |
| EPS Diluted |
-0.49 |
-2.2 |
-1.3 |
-2.95 |
-2.24 |
-1.5 |
-0.58 |
-0.51 |
| Weighted Average Shares
Out |
$43.65 M
|
$43.70 M
|
$43.18 M
|
$40.12 M
|
$35.18 M
|
$28.77 M
|
$33.29 M
|
$33.29 M
|
| Weighted Average Shares
Out Diluted |
$43.65 M
|
$43.70 M
|
$43.18 M
|
$40.12 M
|
$35.18 M
|
$28.77 M
|
$33.29 M
|
$33.29 M
|
| Link |
|
|
|
|
|
|
|
|
